Seminal vesicles

Global Mesenchymal Stem Cells (MSC) Advances and Applications Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
AIDS, Health, Safety, Research, Gene, Gene editing, Seminal vesicles, Ageing, Regenerative medicine, Population, Conditional sentence, Stem cell, Google Trends, Chondrocyte, Prevalence, Company, Exosome, Microsoft, Attention, MSC, B cell, Mesenchymal stem cell, Osteoblast, EVS, Geography, Adipocyte, Growth, Patient, Silk, Pharmaceutical industry

The "Mesenchymal Stem Cells - Advances and Applications, 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells - Advances and Applications, 2022" report has been added to ResearchAndMarkets.com's offering.
  • It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.
  • With the competitive nature of this global market, you do not have the time to do the research.
  • Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.

Evelo Biosciences Announces Grant of Inducement Award

Retrieved on: 
Thursday, September 1, 2022
COVID-19, Inflammation, Research, Seminal vesicles, Ownership, Risk, Psoriasis, U.S. Securities and Exchange Commission, Confidentiality, GLOBE, Nasdaq, Company, Atopic dermatitis, Failure, Marketing, EVS, Private Securities Litigation Reform Act, Growth, Employment, Pharmaceutical industry

The stock option was granted pursuant to the Companys 2021 Employment Inducement Award Plan and was approved by the Companys Board of Directors.

Key Points: 
  • The stock option was granted pursuant to the Companys 2021 Employment Inducement Award Plan and was approved by the Companys Board of Directors.
  • The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to Ms. Thorells entering into employment with the Company.
  • Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference

Retrieved on: 
Thursday, September 1, 2022
COVID-19, Inflammation, Research, Morgan, Seminal vesicles, Ownership, Risk, SEC, Psoriasis, Confidentiality, GLOBE, Conference, Company, Atopic dermatitis, Failure, Investor, Webcast, Marketing, Clinical trial, EVS, Private Securities Litigation Reform Act, Growth, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Health Care Conference on Tuesday, September 13th, 2022 at 12:20 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Health Care Conference on Tuesday, September 13th, 2022 at 12:20 p.m.
  • A live audio webcast of the panel will be available under News and Events in the Investors section of Evelo's website at http://ir.evelobio.com.
  • A replay of the webcast will be available for approximately 30 days following the presentation.
  • Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects.

Extracellular Vesicles 2022: Two Day Conference - Biology, Disease & Medicine (Washington, United States - September 13-14, 2022)

Retrieved on: 
Monday, August 22, 2022
Biological value, Microfluidics, Research, Therapy, Glossary of biology, Biology, Food, Organoid, Drink, Flow cytometry, Conference, Foodservice, Seminal vesicles, EVS, Biomarker, Pharmaceutical industry, Mobile phone

DUBLIN, Aug. 22, 2022 /PRNewswire/ --The "Extracellular Vesicles 2022: Biology, Disease & Medicine" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 22, 2022 /PRNewswire/ --The "Extracellular Vesicles 2022: Biology, Disease & Medicine" conference has been added to ResearchAndMarkets.com's offering.
  • The host is pleased to welcome you all to the Extracellular Vesicles 2022: Biology, Disease & Medicine Conference to be held on-site in-person live in beautiful downtown Seattle.
  • This conference is held co-located and concurrently with the SelectBIO 3D-Models for Drug Testing: Organoids and Tissue Chips 2022 Conference.
  • This Extracellular Vesicles 2022 Conference focuses on the emerging technologies and tools that are driving the field forward.

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Retrieved on: 
Tuesday, August 16, 2022
Multimedia, LG Chem, Inflammatory bowel disease, CEO, Technology, USD, Cosmetics, Scalp, Research, KRW, Acute respiratory distress syndrome, Cell, Aesthetic Surgery Journal, Therapy, Skin, GMP, Exosome, Cosmeceutical, ISEV, Journal of Extracellular Vesicles, Atopic dermatitis, International Society, Journal, Summit, International Society for Extracellular Vesicles, Endoplasmic reticulum, Seminal vesicles, Medical device, Pharmaceutical industry

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.

Key Points: 
  • SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.
  • ExoCoBio will share the significant results of clinical cases of applying ASCE+, regenerative aesthetic product developed by ExoCoBio's manufacturing technology, ExoSCRT for high-efficient and high-purity exosome, to skin and scalp.
  • At this Summit, in particular, Dr. Jan Lotvall and Dr. Sai Kiang Lim, two of the world's best exosome researchers will be invited to present the latest exosome science and interact with attendees.
  • He also said, "In the long run, this Summit will grow into a global platform for exosome industrialization."

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Retrieved on: 
Tuesday, August 16, 2022
LG Chem, Inflammatory bowel disease, CEO, Technology, USD, Cosmetics, Scalp, Research, KRW, Acute respiratory distress syndrome, Cell, Aesthetic Surgery Journal, Therapy, Skin, GMP, Exosome, Cosmeceutical, ISEV, Journal of Extracellular Vesicles, Atopic dermatitis, International Society, Journal, Summit, International Society for Extracellular Vesicles, Endoplasmic reticulum, Seminal vesicles, Medical device, Pharmaceutical industry

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.

Key Points: 
  • SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.
  • ExoCoBio will share the significant results of clinical cases of applying ASCE+, regenerative aesthetic product developed by ExoCoBio's manufacturing technology, ExoSCRT for high-efficient and high-purity exosome, to skin and scalp.
  • At this Summit, in particular, Dr. Jan Lotvall and Dr. Sai Kiang Lim, two of the world's best exosome researchers will be invited to present the latest exosome science and interact with attendees.
  • He also said, "In the long run, this Summit will grow into a global platform for exosome industrialization."

Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 11, 2022
Psoriasis, Inflammation, Toys "R" Us Canada, GLOBE, European Academy of Management, Failure, Private Securities Litigation Reform Act, Growth, SEC, Clinical trial, Poster, Confidentiality, Congress, Research, Marketing, Patient, Review, EVS, COVID-19, Company, Risk, Atopic dermatitis, Seminal vesicles, Webcast, Ownership, US, Flagship Pioneering, ID, Development, Medicine, Administration, Immunity, Pharmaceutical industry, Vaccine, Security (finance), Online gambling, Dermatology

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the second quarter 2022.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the second quarter 2022.
  • This quarter we continued to make substantial progress in our clinical development programs, said Simba Gill, Ph.D., Chief Executive Officer of Evelo.
  • In July 2022, the Company announced the appointment of Marella Thorell as Chief Financial Officer, effective September 1, 2022.
  • ET today to review second quarter 2022 highlights.

Evelo Biosciences Announces Succession Plan

Retrieved on: 
Thursday, August 11, 2022
Psoriasis, Lead, Ara, CEO, Inflammation, GLOBE, Failure, Ara Darzi, Baron Darzi of Denham, Private Securities Litigation Reform Act, Growth, SEC, Board, Spencer Stuart, Confidentiality, Research, Marketing, COVID-19, Company, Biotechnology, Risk, Biology, Atopic dermatitis, Compugen (Israeli company), Seminal vesicles, Board of directors, Ownership, Flagship Pioneering, Time, Chair, Management, Pharmaceutical industry, Flagship, Director

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the succession plan for Simba Gill, Ph.D., to transition from his roles as Chief Executive Officer and President to the role of Chair of the Board of Directors and return to Flagship Pioneering to help launch, grow, and guide bioplatform companies. The Company's Board of Directors has retained Spencer Stuart, a leading executive search firm, to initiate a comprehensive search led by its current Chair, Lord Ara Darzi, to identify Dr. Gill's successor. Dr. Gill will continue to serve as Chief Executive Officer and President until his successor joins Evelo, at which time he will become Chair of the Board of Directors and Lord Darzi will become the Lead Independent Director of Evelo. In addition to serving as Evelo's Chair, Dr. Gill will return to Flagship Pioneering as an Executive Partner to engage in corporate development, platform strategy, and governance across several biotechnology companies in Flagship's portfolio.

Key Points: 
  • Evelo has discovered and developed a new class of investigational medicines targeting the small intestinal axis.
  • Evelo sees the potential of its medicines as a foundation for the treatment of all stages and types of inflammatory diseases.
  • I am very proud of the remarkable discoveries, platform, and clinical development progress that we have made at Evelo.
  • Simba has shown exceptional leadership in building and growing Evelo from its inception until today, said Lord Darzi.

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)